Details
Stereochemistry | ACHIRAL |
Molecular Formula | C27H27N5O3 |
Molecular Weight | 469.535 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 1 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
COCC(=O)NC\C=C\C1=CC2=C(C=C1)N=CN=C2NC3=CC(C)=C(OC4=CC=C(C)N=C4)C=C3
InChI
InChIKey=LLVZBTWPGQVVLW-SNAWJCMRSA-N
InChI=1S/C27H27N5O3/c1-18-13-21(8-11-25(18)35-22-9-6-19(2)29-15-22)32-27-23-14-20(7-10-24(23)30-17-31-27)5-4-12-28-26(33)16-34-3/h4-11,13-15,17H,12,16H2,1-3H3,(H,28,33)(H,30,31,32)/b5-4+
Molecular Formula | C27H27N5O3 |
Molecular Weight | 469.535 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 1 |
Optical Activity | NONE |
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/17285315Curator's Comment: description was created based on several sources, including
https://clinicaltrials.gov/ct2/show/NCT00055926 | https://clinicaltrials.gov/ct2/show/NCT00102895
Sources: https://www.ncbi.nlm.nih.gov/pubmed/17285315
Curator's Comment: description was created based on several sources, including
https://clinicaltrials.gov/ct2/show/NCT00055926 | https://clinicaltrials.gov/ct2/show/NCT00102895
CP 724714 is an orally bioavailable, quinazoline-based, selective small molecule inhibitor of the HER2/erbB2 receptor tyrosine kinase. The compound could have particular potential in the treatment of women with metastatic breast cancer, of which 25-30% over express HER2/erbB2. CP 724714 was in preclinical development with Pfizer.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL1824 Sources: https://www.ncbi.nlm.nih.gov/pubmed/17285315 |
32.0 nM [IC50] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Unknown Approved UseUnknown |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
4900 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/17317835 |
400 mg 2 times / day multiple, oral dose: 400 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
CP-724714 plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
4900 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/17805538 |
400 mg 2 times / day single, oral dose: 400 mg route of administration: Oral experiment type: SINGLE co-administered: |
CP-724714 plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
4940 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/17805538 |
400 mg 2 times / day multiple, oral dose: 400 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
CP-724714 plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
4940 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/17317835 |
400 mg 2 times / day steady-state, oral dose: 400 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
CP-724714 plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
2740 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/17317835 |
250 mg 2 times / day multiple, oral dose: 250 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
CP-724714 plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
3660 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/17317835 |
250 mg 2 times / day steady-state, oral dose: 250 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
CP-724714 plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
11900 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/17317835 |
400 mg 2 times / day multiple, oral dose: 400 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
CP-724714 plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
11900 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/17805538 |
400 mg 2 times / day single, oral dose: 400 mg route of administration: Oral experiment type: SINGLE co-administered: |
CP-724714 plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
14900 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/17805538 |
400 mg 2 times / day multiple, oral dose: 400 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
CP-724714 plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
14900 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/17317835 |
400 mg 2 times / day steady-state, oral dose: 400 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
CP-724714 plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
7360 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/17317835 |
250 mg 2 times / day multiple, oral dose: 250 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
CP-724714 plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
9300 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/17317835 |
250 mg 2 times / day steady-state, oral dose: 250 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
CP-724714 plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
4.34 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/17317835 |
400 mg 2 times / day multiple, oral dose: 400 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
CP-724714 plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
4.34 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/17805538 |
400 mg 2 times / day single, oral dose: 400 mg route of administration: Oral experiment type: SINGLE co-administered: |
CP-724714 plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
4.8 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/17317835 |
250 mg 2 times / day multiple, oral dose: 250 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
CP-724714 plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
Doses
Dose | Population | Adverse events |
---|---|---|
400 mg 2 times / day multiple, oral Highest studied dose Dose: 400 mg, 2 times / day Route: oral Route: multiple Dose: 400 mg, 2 times / day Sources: Page: p.108 |
unhealthy, ADULT n = 5 Health Status: unhealthy Condition: cancer Age Group: ADULT Sex: M+F Food Status: FASTED Population Size: 5 Sources: Page: p.108 |
|
400 mg 2 times / day multiple, oral Highest studied dose Dose: 400 mg, 2 times / day Route: oral Route: multiple Dose: 400 mg, 2 times / day Sources: Page: p.1241 |
unhealthy, ADULT n = 5 Health Status: unhealthy Condition: cancer Age Group: ADULT Sex: M+F Food Status: UNKNOWN Population Size: 5 Sources: Page: p.1241 |
DLT: Hyperbilirubinemia, ALT increased... Dose limiting toxicities: Hyperbilirubinemia (grade 3, 20%) Sources: Page: p.1241ALT increased (grade 3, 20%) |
250 mg 2 times / day multiple, oral RP2D Dose: 250 mg, 2 times / day Route: oral Route: multiple Dose: 250 mg, 2 times / day Sources: Page: p.1241 |
unhealthy, ADULT n = 15 Health Status: unhealthy Condition: cancer Age Group: ADULT Sex: M+F Food Status: FASTED Population Size: 15 Sources: Page: p.1241 |
DLT: thrombocytopenia, Pulmonary embolism... Dose limiting toxicities: thrombocytopenia (grade 3, 6.7%) Sources: Page: p.1241Pulmonary embolism (grade 4, 6.7%) |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
ALT increased | grade 3, 20% DLT |
400 mg 2 times / day multiple, oral Highest studied dose Dose: 400 mg, 2 times / day Route: oral Route: multiple Dose: 400 mg, 2 times / day Sources: Page: p.1241 |
unhealthy, ADULT n = 5 Health Status: unhealthy Condition: cancer Age Group: ADULT Sex: M+F Food Status: UNKNOWN Population Size: 5 Sources: Page: p.1241 |
Hyperbilirubinemia | grade 3, 20% DLT |
400 mg 2 times / day multiple, oral Highest studied dose Dose: 400 mg, 2 times / day Route: oral Route: multiple Dose: 400 mg, 2 times / day Sources: Page: p.1241 |
unhealthy, ADULT n = 5 Health Status: unhealthy Condition: cancer Age Group: ADULT Sex: M+F Food Status: UNKNOWN Population Size: 5 Sources: Page: p.1241 |
thrombocytopenia | grade 3, 6.7% DLT |
250 mg 2 times / day multiple, oral RP2D Dose: 250 mg, 2 times / day Route: oral Route: multiple Dose: 250 mg, 2 times / day Sources: Page: p.1241 |
unhealthy, ADULT n = 15 Health Status: unhealthy Condition: cancer Age Group: ADULT Sex: M+F Food Status: FASTED Population Size: 15 Sources: Page: p.1241 |
Pulmonary embolism | grade 4, 6.7% DLT |
250 mg 2 times / day multiple, oral RP2D Dose: 250 mg, 2 times / day Route: oral Route: multiple Dose: 250 mg, 2 times / day Sources: Page: p.1241 |
unhealthy, ADULT n = 15 Health Status: unhealthy Condition: cancer Age Group: ADULT Sex: M+F Food Status: FASTED Population Size: 15 Sources: Page: p.1241 |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/17285315
In phase I-II clinical trials subjects received CP-724,714 as continuous oral daily doses on 21-day cycles for a predefined maximal duration of 17 cycles (51 weeks). There was no washout between cycles. The starting dose level was 250 mg QD. In subsequent dose cohorts, 250 mg BID, 400 mg BID, and 250 mg TID were evaluated. The maximal tolerated dose was identified as 250 mg TID.
Route of Administration:
Oral
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 07:42:48 UTC 2023
by
admin
on
Sat Dec 16 07:42:48 UTC 2023
|
Record UNII |
I05QZ0S4V3
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Code | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Code | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C1967
Created by
admin on Sat Dec 16 07:42:49 UTC 2023 , Edited by admin on Sat Dec 16 07:42:49 UTC 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
9874913
Created by
admin on Sat Dec 16 07:42:49 UTC 2023 , Edited by admin on Sat Dec 16 07:42:49 UTC 2023
|
PRIMARY | |||
|
CHEMBL483321
Created by
admin on Sat Dec 16 07:42:49 UTC 2023 , Edited by admin on Sat Dec 16 07:42:49 UTC 2023
|
PRIMARY | |||
|
DB12302
Created by
admin on Sat Dec 16 07:42:49 UTC 2023 , Edited by admin on Sat Dec 16 07:42:49 UTC 2023
|
PRIMARY | |||
|
383432-38-0
Created by
admin on Sat Dec 16 07:42:49 UTC 2023 , Edited by admin on Sat Dec 16 07:42:49 UTC 2023
|
PRIMARY | |||
|
DTXSID401026009
Created by
admin on Sat Dec 16 07:42:49 UTC 2023 , Edited by admin on Sat Dec 16 07:42:49 UTC 2023
|
PRIMARY | |||
|
167658
Created by
admin on Sat Dec 16 07:42:49 UTC 2023 , Edited by admin on Sat Dec 16 07:42:49 UTC 2023
|
PRIMARY | |||
|
537705-08-1
Created by
admin on Sat Dec 16 07:42:49 UTC 2023 , Edited by admin on Sat Dec 16 07:42:49 UTC 2023
|
NON-SPECIFIC STEREOCHEMISTRY | |||
|
I05QZ0S4V3
Created by
admin on Sat Dec 16 07:42:49 UTC 2023 , Edited by admin on Sat Dec 16 07:42:49 UTC 2023
|
PRIMARY | |||
|
300000041486
Created by
admin on Sat Dec 16 07:42:49 UTC 2023 , Edited by admin on Sat Dec 16 07:42:49 UTC 2023
|
PRIMARY | |||
|
C26648
Created by
admin on Sat Dec 16 07:42:49 UTC 2023 , Edited by admin on Sat Dec 16 07:42:49 UTC 2023
|
PRIMARY | NCIT |
Related Record | Type | Details | ||
---|---|---|---|---|
|
SALT/SOLVATE -> PARENT |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |